Medical/Pharmaceuticals
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring full intellectual property rights of BRII-179 and expanding it...
2024-03-22 19:00
3346
The Results of Phase II Clinical Study of KN046 Plus Chemotherapy as First-line Treatment for Metastatic NSCLC were Published in Cell Reports Medicine
SUZHOU, China, March 22, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the phase II clinical research results of anti- PD-L1/CTLA-4 bispecific antibody KN046 plus chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC) were published o...
2024-03-22 18:42
2438
Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress Across First-in-Class, Best-in-Class Pipeline
* Promising clinical activities and efficacies during dose escalations for four lead global rights programs targeting CD24, Claudin 18.2, CD73, and PD-L1/4-1BB * Positive, differentiated cervical cancer data advancing mTORC1/2 inhibitor on registrational track for APAC markets * RMB1.188 bi...
2024-03-22 18:00
5793
NeuExcell Therapeutics Announces Successful Dosing of First Patient by NeuroD1 Gene Therapy
SUZHOU, China, March 22, 2024 /PRNewswire/ -- NeuExcell Therapeutics, a leading biotechnology company focused onin vivo neural regenerative therapies, announces the successful dosing of the first patient with the first-in-class NeuroD1 gene therapy product NXL-004. This milestone represents si...
2024-03-22 08:00
1849
Lynk Pharmaceuticals Announces First Atopic Dermatitis Patient Dosed in Phase Ⅲ Clinical Study of LNK01001
BOSTON and HANGZHOU and SHANGHAI, China, March 22, 2024 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, announced that it has dosed the first patient with Atopic Dermatitis (AD) in a Phase Ⅲ ...
2024-03-22 08:00
1865
OcuMension (01477.HK) Invests Over RMB 123.8 Million in Research, Technology and Self-development Progress in Tandem, Main Product Sales Show Comprehensive Growth
SHANGHAI, March 21, 2024 /PRNewswire/ -- On the evening of March 21st, OcuMension Therapeutics (Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "OcuMension" or the "Company") disclosed its 2023 annual performance report. The company achieved a total operating income ofRMB 246.4 million ...
2024-03-21 22:44
3181
Henlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a net profit RMB546 million, first full-year profitability achieved
SHANGHAI, March 21, 2024 /PRNewswire/ -- Henlius (2696.HK) announced its 2023 annual results. During the reporting period, Henlius' revenue reached about RMB5.3949 billion, representing an increase of 67.8% YoY, and recorded a net profit ofRMB546.0 million. This is the first time for Henlius to a...
2024-03-21 19:47
2983
SK bioscience Exports Influenza Vaccine to Thailand, Entering Southern Hemisphere Market
* Company exported 440,000 doses to Thailand, marking its entry into the Southeast Asian market and the Southern Hemisphere market. * Company has obtained marketing authorizations in 12 countries, with additional approvals underway in 10 countries to expand its market worldwide. BANGKOK and S...
2024-03-21 13:24
1549
SINGAPORE'S "HUSTLE CULTURE" TAKES ITS TOLL: THE AIR STATION AND RESMED LAUNCH INITIATIVE TO ADDRESS WORK-INDUCED SLEEP ISSUES
* Global survey reveals that 39% of Singaporeans grapple with sleep, impacting health and productivity. * The Air Station and ResMed's upcoming joint initiative, "Discover Your Sleep Superpowers," aims to empower Singaporeans with free sleep screenings, complimentary sleep consultations with ...
2024-03-21 09:35
1480
TreeFrog's Chief Scientific Officer & Co-founder, Maxime Feyeux, to present at The 23rd Congress of the Japanese Society for Regenerative Medicine (JSRM)
- TreeFrog Therapeutics demonstrates fast, sustained, full motor recovery in preclinical models for Parkinson's Disease cell therapy program using C-Stem™ proprietary technology[1] - BORDEAUX, France, March 21, 2024 /PRNewswire/ -- TreeFrog Therapeutics, a cell therapy development company with...
2024-03-21 07:30
1475
Jiangsu Recbio Technology Co., Ltd. announced 2023 annual results report and latest progress
TAIZHOU, China, March 21, 2024 /PRNewswire/ -- Innovative vaccine company Recbio (02179.HK) announced its latest progress and annual results for 2023. The company always adhered to the mission of " Protect Human Health With Best-In-Class Vaccines", and achieved the following milestones and progre...
2024-03-21 00:22
2823
Antengene Initiates Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia
SHANGHAI and HONG KONG, March 20, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in he...
2024-03-20 20:30
2079
Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study
* ATN-031 (also known as ATG-031), is the first anti-CD24 antibody to advance to the clinic in oncology inthe United States * The Phase I PERFORM trial, ongoing at four major U.S. cancer centers, is evaluating the safety and preliminary efficacy of ATN-031 in patients with advanced solid tumor...
2024-03-20 20:30
2143
Innovent Announces 2023 Annual Results and Business Updates
A transformative year of strong performance and material innovation progress ROCKVILLE, M.D. and SUZHOU, China, March 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality med...
2024-03-20 19:44
3139
Johnson Matthey signs agreement to sell its Medical Device Components business for US$700m
Johnson Matthey Plc This announcement contains inside information LONDON, March 20, 2024 /PRNewswire/ -- Johnson Matthey Plc (JM) announces that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consider...
2024-03-20 19:10
2026
STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses
LAKE FOREST, Calif., March 20, 2024 /PRNewswire/ -- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that more than three million ICLs have bee...
2024-03-20 16:22
1683
BGI Group Celebrates 20th Anniversary of Partnerships in Healthcare and Genomics in Thailand
BANGKOK, March 20, 2024 /PRNewswire/ -- This year marks the twentieth anniversary of BGI Group's close relationship with the Kingdom ofThailand. Initially both parties were brought together through an international humanitarian rescue effort during the Indian Ocean tsunami where BGI worked with ...
2024-03-20 12:39
1710
Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies
Proceeds to Support Advancement of Engrail's Pipeline for Neuropsychiatric and Neurodevelopmental Disorders SAN DIEGO, March 20, 2024 /PRNewswire/ -- Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the development of transformational therapies to impro...
2024-03-20 11:00
1496
Docquity enables Italian biopharmaceutical company Menarini to double HCP reach and engagement in Malaysia
* A Docquity client since 2021, Menarini Malaysia further engaged the platform to raise awareness among target HCPs on multimodal approaches to post-surgery pain management and recovery * Docquity's Awareness to Advocacy (A2A) Program, backed by its in-depth HCP network insights, droveMenarini...
2024-03-20 10:00
1470
Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients
SHANGHAI, March 20, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative medicines and vaccines, announced today that the Singapore Health Sciences ...
2024-03-20 09:16
1464
Week's Top Stories
Most Reposted
Protiviti Transforms Cyber Risk Consulting with CYFIRMA's Advanced Intelligence-Led Cybersecurity
[Picked up by 324 media titles]
2024-04-15 09:00Sephora appoints Xia Ding as Managing Director of Sephora Greater China
[Picked up by 309 media titles]
2024-04-15 17:33
With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
[Picked up by 282 media titles]
2024-04-18 21:26
Animated Life in Yunnan
[Picked up by 278 media titles]
2024-04-18 14:00
China's Yiwu Establishes Welcoming Committee to Attract International Buyers
[Picked up by 277 media titles]
2024-04-19 13:25
Most Read
Combining Sustainability and Cybersecurity: Century Iron & Steel and Century Wind Power Both Receive ISO 27001 Information Security Certification
2024-04-19 18:03
4360
Sephora appoints Xia Ding as Managing Director of Sephora Greater China
2024-04-15 17:33
3832
Allianz Partners Introduces Instant Online Chat for HCF Travel Insurance Customers
2024-04-15 08:00
3096
Goldpac Exhibits at InnoEx 2024
2024-04-13 10:00
3040